Table 2 Immunophenotype distribution in 622 cases of mature T-cell and NK-cell lymphoma
Immunophenotype | Total [cases (%)] | Male/female ratio | Age [years, median (range)] |
|---|---|---|---|
Extranodal NK/T-cell lymphoma, nasal type | 317 (51.0) | 217/100 | 43.0 (10–86) |
Angioimmunoblastic T-cell lymphoma | 118 (19.0) | 82/36 | 63.0 (36–87) |
Peripheral T-cell lymphoma, not otherwise specified | 81 (13.0) | 58/23 | 49.0 (25–81) |
Anaplastic large-cell lymphoma, ALK-positive | 31 (5.0) | 19/12 | 21.0 (4–69) |
Anaplastic large-cell lymphoma, ALK-negative | 15 (2.4) | 10/5 | 45.0 (8–76) |
Primary cutaneous, anaplastic large-cell lymphoma |  |  | 48.0 (24–81) |
13 (2.1) | 4/9 | 7.5 (2–13) | |
Hydroa vacciniforme-like LPD | 12 (1.9) | 8/4 | Â |
Subcutaneous panniculitis-like T-cell lymphoma | 12 (1.9) | 5/7 | 36.0 (17–55) |
Monomorphic epitheliotropic intestinal T-cell lymphoma | 9 (1.4) | 6/3 | 50.0 (38–82) |
Hepatosplenic T-cell lymphoma | 5 (0.8) | 4/1 | 37.0 (29–44) |
Primary cutaneous CD4-positive small/medium T-cell LPD | 3 (0.4) | 3/0 | 40.0 (22–60) |
Primary cutaneous γδ T-cell lymphoma | 2 (0.3) | 1/1 | 19.0 (2–36) |
Mycosis fungoides | 2 (0.3) | 1/1 | 29.0 (18–40) |
Aggressive NK-cell leukemia | 2 (0.3) | 2/0 | 27.0 (22–32) |
Total | 622 | 420/202 | 47.5 (2–87) |